Waystar also captures revenue that might otherwise be lost by helping providers uncover unknown insurance coverage before care begins — achieving up to a 55% discovery rate for patients previously deemed uninsured. Combined with pre-service estimation, providers can set clear cost expectations — accelerating collections, protecting revenue, and improving the patient experience. With more than a decade of consecutive Best in KLAS recognition, Waystar continues to set the standard for healthcare payments by d ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund focuses on long-term, competitively positioned companies that are well-managed and have significant potential in untapped markets. The letter also addressed the advancements in AI and how humans define themselves in the changing landscape. In Q4, the fund generated a return of 0.19% (Institutional Shares), underperforming the Russell 2 ...

My recommendation for Waystar Holding Corp. ( WAY ) is a buy rating. I believe WAY has a scalable and defensible business model, supported by its distribution and technical moat. With AI improving the product rather thanI focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-term. ...

Waystar Holding Corp. (NASDAQ:WAY) is one of the best US stocks to buy under $50. On January 16, analysts at BofA Securities reiterated a Buy rating and a $52 price target on Waystar Holding Corp. (NASDAQ:WAY). According to the research, the company is well-positioned to benefit as customers plan to replace and spend more on the revenue cycle. Waystar Holding Corp. (WAY) Gains Analyst Confidence with Strong Market Position and Growth Potential The fact that 74% of hospitals don’t plan to change their rev ...

Core Viewpoint - The healthcare industry is experiencing significant advancements due to AI, with Waystar identified as a top investment opportunity for 2026 due to its strategic position in high-growth software and addressing administrative inefficiencies [1] Group 1: Company Performance and Strategy - Waystar's stock has declined by 20% over the past year, but analysts believe its growth potential is undervalued [1] - The company faced challenges post its $1.25 billion acquisition of Iodine software in late 2025, but is now seeing operational integration [2] - Waystar has maintained an aggressive consolidation strategy, executing over 10 acquisitions since its formation in 2017 and processing over 7.5 billion transactions annually [4] Group 2: Market Dynamics and Opportunities - Hospitals are seeking new revenue cycle vendors due to the cybersecurity breach at Change Healthcare, creating opportunities for differentiated players like Waystar [3] - The rapid growth of AI is prompting hospitals to adapt their platforms, further benefiting companies like Waystar [3] - Waystar's "AltitudeAI" tool addresses the $20 billion denial problem in the industry, significantly speeding up denial appeals processing from 38 hours to just 2 hours [6] Group 3: Analyst Insights and Projections - Analysts project that Waystar's roll-up strategy could unlock 400 to 500 basis points in margin upside as it integrates AI and scales [4] - The shift towards an "autonomous revenue cycle" driven by AI is expected to reshape market dynamics, with Waystar positioned as a key beneficiary [5] - Other notable players in the market include Phreesia and Health Catalyst, although they operate on different scales and specialties [6]

分组1: Microsoft - Microsoft has significantly invested in AI, with a $13.8 billion investment in OpenAI, acquiring a 27% stake and securing a commitment for $250 billion in Azure services [1] - The company reported fiscal Q1 2026 revenue of $77.7 billion, an 18% year-over-year increase, and a non-GAAP EPS of $4.13, beating estimates by 47 cents [7] - Microsoft's cloud revenue grew by 26% in fiscal Q1, with Azure and other cloud services revenue increasing by 40% [8] - UBS analyst Karl Kierstead maintains a Buy rating on Microsoft, projecting a price target of $650, indicating a potential 36% gain over the next 12 months [9] 分组2: Waystar Holding - Waystar is an AI technology company in the healthcare sector, facilitating payment processes for providers and handling over 6 billion annual healthcare payment transactions [10][12] - The company reported Q3 2025 revenues of $268.7 million, a 12% year-over-year increase, and a non-GAAP EPS of 37 cents, exceeding expectations [13] - UBS analyst Kevin Caliendo rates Waystar as a Buy, with a price target of $41, suggesting a 30% upside potential, supported by its acquisition of Iodine Software and expected growth in AI adoption [14]

Core Insights - Waystar is establishing industry leadership in the healthcare revenue cycle sector, positioning itself as a cloud-native platform with extensive capabilities and feature improvements [2] - The company is actively deploying AI solutions across its platform, transitioning from hype to delivering real value to clients [2] - Waystar has an ambitious product roadmap that aims to enhance its service offerings and maintain a long-term competitive advantage [2]

Waystar FY Conference Summary Company Overview - **Company**: Waystar (NasdaqGS:WAY) - **Industry**: Healthcare Revenue Cycle Management - **CEO**: Matt Hawkins Core Points and Arguments - **Industry Leadership**: Waystar is establishing itself as a leader in the healthcare revenue cycle management sector, utilizing a cloud-native platform that offers numerous capabilities and features to clients each quarter [3][4] - **AI Integration**: The company is deploying AI solutions across its platform, transitioning from hype to delivering real value to clients [3][4] - **Market Opportunity**: Waystar is targeting a large and growing addressable market, estimated at $20 billion, with potential expansion into a $100 billion revenue cycle services market [10][11] - **Proven Growth Model**: The company has consistently exceeded revenue and EBITDA guidance for six consecutive quarters, demonstrating a durable growth model [5][21] - **Proprietary Data**: In 2025, Waystar processed 7.5 billion insurance transactions, representing over $2.5 trillion in gross claim charges, providing a significant proprietary data advantage for developing AI solutions [5][6][39] - **Client Base**: Waystar serves over a million providers, reaching more than 60% of the U.S. patient population annually, and has a strong client retention rate of 97% [16][24] Key Metrics - **Claim Acceptance Rate**: The platform boasts a nearly 99% first-pass claim acceptance rate, significantly higher than competitors [13][18] - **Denied Claims Prevention**: In 2025, Waystar prevented nearly $16 billion in denied claims, showcasing the effectiveness of its solutions [18][31] - **Revenue Retention**: Gross revenue retention stands at 97%, with net revenue retention averaging between 108% and 110% [24] Strategic Initiatives - **Acquisition of Iodine**: The acquisition of Iodine, which processes one out of every three hospital-based patient discharges in the U.S., enhances Waystar's data capabilities and AI solution development [6][27] - **End-to-End AI Solutions**: Waystar is developing an end-to-end AI-powered software platform that integrates various stages of the revenue cycle, improving efficiency and reducing manual errors [12][14] - **Channel Partnerships**: The company has over 500 integrations with practice management and EHR vendors, enhancing its market reach and operational efficiency [17][48] Future Outlook - **Growth Levers**: Waystar plans to expand its market share, currently at 5% in hospitals and 9% in ambulatory settings, indicating significant room for growth without needing new software solutions [25] - **Pipeline and Win Rates**: The company reports a robust pipeline with an 80% win rate against competitors, indicating strong market demand for its solutions [22][45] - **AI Development**: Waystar is moving towards more autonomous AI capabilities, aiming to create agents that can perform complex tasks, further enhancing operational efficiency [34][35] Additional Insights - **Administrative Waste**: The healthcare industry faces nearly $500 billion in administrative waste, presenting a significant opportunity for Waystar to streamline processes and reduce costs [9] - **Cybersecurity Focus**: Decision-makers prioritize cybersecurity and prefer fewer vendors, positioning Waystar favorably in the market [37][38] - **Utilization Trends**: The company is well-positioned to assist providers during both high and normalized utilization periods, ensuring continued demand for its services [42][44] This summary encapsulates the key points from Waystar's FY conference, highlighting the company's strategic direction, market position, and future growth potential.

J.P. MORGAN CONFERENCE Waystar Overview January 12, 2026 ADMIN ACCOUNT ANALYTICS PATIENT TOOLS Executive Dashboard Enaces Explore 32 4.82% Average Days to Pay Denial Rate ▼ 5.3% Previous Month Change ▼ -21% Previous Month Change Payment Trend May Apri NESCH February Recelved Manth Denial Rate Trend Summary March April May June July Received Month WAYSTAR FORWARD-LOOKING STATEMENTS This presentation contains forvard looking statements, within the meaning of the Private Securities Litigstion Reform Act of P99 ...

Company Overview - Waystar provides a cloud-based software platform focused on healthcare payments, including financial clearance, patient financial care, claims and payment management, denial prevention, revenue capture, and analytics solutions [5][8] - The company generates revenue through subscription and transaction-based fees, primarily serving hospitals, physician groups, and other healthcare organizations [12] Financial Performance - As of Thursday, Waystar's stock was priced at $33.08, with a market capitalization of $6 billion [5] - The company reported a total revenue of $1.04 billion and a net income of $111.18 million for the trailing twelve months (TTM) [5] - In the third quarter, Waystar achieved revenue of $268.7 million, reflecting a year-over-year growth of 12%, alongside an adjusted EBITDA margin of 42% and a net revenue retention rate of 113% [9] Recent Developments - Westwind Capital sold its entire position in Waystar, liquidating 420,897 shares for an estimated $15.96 million, reducing its stake to zero [2][3][6] - This position had previously represented 3.3% of Westwind Capital's assets under management (AUM) [4][6] - Despite Waystar's recent growth, Westwind Capital's decision to exit indicates concerns over the stock's performance, which has declined nearly 12% over the past year, underperforming the S&P 500 by nearly 30 percentage points [4][10] Market Position and Strategy - Waystar is positioned in the healthcare payments sector, benefiting from structural tailwinds in healthcare payments automation [11] - The company is scaling profitably, generating $82 million in operating cash flow in the quarter, but faces leverage and integration risks following recent acquisitions [11]